New Clinical Findings Enhance CAPLYTA®'s Promise for Major Depressive Disorder Remission Recent data reveals that CAPLYTA® (lumateperone) significantly increases remission rates in adults with major depressive disorder, offering hope for better treatment outcomes.

New Clinical Findings Enhance CAPLYTA®'s Promise for Major Depressive Disorder Remission #United_States #Titusville #Major_Depressive_Disorder #CAPLYTA® #lumateperone

🚨 New RCT: Lumateperone for MDD & bipolar depression w/ mixed features

✅ Improved MADRS scores vs placebo
✅ No mania induction
✅ Low akathisia, minimal weight gain

A new option for hard-to-treat mixed states

#mentalhealth #Psychiatry #MDD #BipolarDisorder #Lumateperone #Mentalhealthmatters